After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
The deal is expected to close in Q2 2026, subject to approvals, with the combined company focused on advancing YB-101 (GS-098) for Graves’ disease and thyroid eye disease.